Analysis Method of Real-World Digital Biomarkers for Clinical Impact in Cancer Patients.

Ingrid Oakley-Girvan^1,2, Yaya Zhai³, Reem Yunis¹, Raymond Liu^4,5, Sharon W Davis¹, Ai Kubo⁴, Sara Aghaee⁴, Jennifer M Blankenship³, Kate Lyden³, Elad Neeman⁶

¹Medable Inc., Strategy and Science Departments, Palo Alto, CA, USA.

²Public Health Institute, The Data and Technology Proving Ground, Oakland, CA, USA.

³Vivosense, Inc., Newport Coast, CA, USA.

⁴Kaiser Permanente Northern California, Division of Research, Oakland, CA, USA.

⁵Kaiser Permanente Northern California, Department of Hematology Oncology, San Francisco, CA, USA.

⁶Kaiser Permanente Northern California, San Rafael Medical Center, San Rafael, CA, USA.

PubMed PMC DOI PDF

Abstract

INTRODUCTION: Wearable technologies can enhance measurements completed from home by participants in decentralized clinical trials. These measurements have shown promise in monitoring patient wellness outside the clinical setting. However, there are challenges in handling data and its interpretation when using consumer wearables, requiring input from statisticians and data scientists. This article…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.